Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for Prevention of Delayed CINV
NCT02203253Phase 3Completed
- Sponsor
- China Medical University
- Start
- Jul 2014
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of thalidomide in chemotherapy-induced nausea and vomiting (CINV), sponsored by China Medical University. Started Jul 2014; status: completed.
02
Drugs
thalidomide
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT02203253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02203253.